Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

11.72 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 11.72
Bid (Size) 11.01 (1)
Ask (Size) 11.71 (1)
Prev. Close 11.72
Today's Range 11.72 - 11.72
52wk Range 3.210 - 18.33
Shares Outstanding 279,307,043
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Iovance Biotherapeutics Stock a Buy Now?
Let's find out if this biotech can keep up its recent momentum. 
Via The Motley Fool
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI. 
Via MarketBeat
Topics Cannabis
Exposures Cannabis

Performance

YTD
+44.69%
+44.69%
1 Month
-15.68%
-15.68%
3 Month
+47.61%
+47.61%
6 Month
+255.15%
+255.15%
1 Year
+100.51%
+100.51%

More News

Read More
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
Via The Motley Fool
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics
Via Benzinga
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
Via InvestorPlace
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead
Via The Motley Fool
Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know
Via Benzinga
Truist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To Know
Via Benzinga
Spotlight on Iovance Biotherapeutics: Analyzing the Surge in Options Activity
Via Benzinga
Iovance Biotherapeutics: Q4 Earnings Insights
Via Benzinga
Iovance Biotherapeutics's Earnings: A Preview
Via Benzinga
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?
Via The Motley Fool
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst
Via The Motley Fool
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Could Iovance Biotherapeutics Stock Help You Become a Millionaire?
Via The Motley Fool
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Why Iovance Biotherapeutics Stock Got Trounced on Thursday
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy?
Via The Motley Fool
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
3 Stocks Flashing Recent Insider Buying Signals
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.